Ecuador
Tuberculosis profile
Population  2012 15 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.41 (0.35–0.48) 2.7 (2.3–3.1)
Mortality (HIV+TB only) 0.27 (0.23–0.34) 1.8 (1.5–2.2)
Prevalence  (includes HIV+TB) 15 (7.6–25) 98 (49–163)
Incidence  (includes HIV+TB) 9.1 (7.5–11) 59 (48–70)
Incidence (HIV+TB only) 0.84 (0.7–1) 5.4 (4.5–6.5)
Case detection, all forms (%) 60 (50–73)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 856 (75) Relapse 348 (52)
Smear-negative 285 (6) Treatment after failure 20 (3)
Smear-unknown / not done 0 (0) Treatment after default 136 (21)
Extrapulmonary 856 (17) Other 159 (24)
Other 111 (2)      
Total new 5 108   Total retreatment 663  
           
Other (history unknown)          
Total new and relapse 5 456   Total cases notified 5 771  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.8 1.9 1.4
Age < 15 96 59 48
Laboratories 2012
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 5.8
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 78   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 62  
Retreatment 35  
TB/HIV 2012 Number (%)
TB patients with known HIV status 4 974 (86)
HIV-positive TB patients 669 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 4.9 (3.5–6.7) 26 (23–29)
MDR-TB cases among notified pulmonary
TB cases
210 (150–280) 170 (150–190)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 529 (13%) 827 (125%) 1 356
Laboratory-confirmed MDR-TB cases 8 215 223
Patients started on MDR-TB treatment     196
Financing TB control 2013
National TB programme budget (US$ millions) 7.3
% Funded domestically 89%
% Funded internationally 11%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data